Abstract
By measuring the cerebral infarction rate and neurological behavioral score of rats in a sham operation group, an MCAO model control group and an Erigeron breviscapus injection treatment group, we explored the therapeutic effects of Erigeron breviscapus injection on brain tissue and neuroethological injury in rats. Plasma samples were collected at 18 time points after intravenous injection of Erigeron breviscapus. The levels of scutellarin, 4-caffeoylquinic acid, 5-caffeoylquinic acid, 3,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, chlorogenic acid and isochlorogenic acid B in rat plasma at the various time points were determined by an HPLC method, and drug concentration versus time plots were constructed to estimate the pharmacokinetic parameters. Finally, a PK-PD combined model was used to analyze the relationship between the blood concentration, time and therapeutic effects of the seven active components. The results of the pharmacodynamics studies showed that the cerebral infarction rate of rats in the Erigeron breviscapus injection group decreased significantly at 5 min, 10 min, 20 min, 6 h, 8 h, 18 h, 24 h, 32 h, 40 h and 48 h after cerebral ischemia. Abnormal neurological behavior scores were significantly reduced after 4 h of cerebral ischemia. The pharmacokinetics results showed that the seven chemical constituents in Erigeron breviscapus injection reached their highest detection value after 5 min of cerebral ischemia. The lowest detection values of scutellarin and isochlorogenic acid B appeared after 6 h of cerebral ischemia but could not be detected after 8 h. The lowest detection values of 5-caffeoylquinic acid and 4,5-dicaffeoylquinic acid were found in the third hour of cerebral ischemia but not after 4 h. The lowest detection values of 4-caffeoylquinic acid, 3,5-dicaffeoylquinic acid and chlorogenic acid were found during the second hour of cerebral ischemia but not at the third hour. However, at 18 h, 24 h, 32 h and 40 h of cerebral ischemia, the cerebral infarction rates of rats in the Erigeron breviscapus injection group were significantly reduced, with decreased values of 6.22%, 11.71%, 6.92% and 4.96%, respectively, and the effects were stronger than those after 5–20 min of cerebral ischemia. The decreased values reached their highest value after 24 h of cerebral ischemia. Our results show that the effects of Erigeron breviscapus injection on reducing the cerebral infarct rate in MCAO model rats are characterized by a fast onset and long maintenance time. The 5-min blood concentration in cerebral ischemia was the highest test value, and after this time, the cerebral infarction rate of MCAO rats began to decrease. However, the peak value of the effects lagged behind that of the plasma concentration. The maximum effective time for Erigeron breviscapus injection appeared 24 h after cerebral ischemia, which provides a reference for the screening of specific drugs for ischemic stroke, optimal dosing regimens and rational clinical drug use.
Graphical Abstract
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- PK:
-
Pharmacokinetics
- PD:
-
Pharmacodynamics
- MCAO:
-
Middle cerebral artery occlusion
- TTC:
-
2,3,5-Triphenyltetrazolium chloride
- HPLC:
-
High-performance liquid chromatography
- RSD:
-
Relative standard deviation
- Tmin :
-
Minimum time
- Tmax :
-
Maximum time
- T1/2 :
-
Half-life
- MRT:
-
Mean residence time
- Emax :
-
Maximal effect
- AUCtot :
-
Total area under the curve
- R:
-
Correlation coefficient
- R2 :
-
Square of the correlation coefficient
References
Chen Q (2006) Methodology of pharmacology of traditional Chinese medicine. Beijing: People's Health Press 493:539–540
Chen Q, Dong XC, Shi SJ et al (2004) Study on the pharmacokinetics–pharmacodynamics of daurisoline and dauricine in Beagle dogs. Chin J Pharm 39(5):366–368. https://doi.org/10.3321/j.issn:1001-2494.2004.05.018
Chen X, Zhao Z, Chen Y et al (2016) Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats. J Ethnopharmacol 192:362–369. https://doi.org/10.1016/j.jep.2016.07.066
Deng Y, Xiong D, Yin C et al (2016) Icariside II protects against cerebral ischemia-reperfusion injury in rats via nuclear factor-κB inhibition and peroxisome proliferator-activated receptor up-regulation[J]. Neurochem Int 96:56–61. https://doi.org/10.1016/j.neuint.2016.02.015
Derendor FH, Meibohm B (1996) Modeling of pharmacokinetics/pharmacodynamics(PK/PD) relationship: concepts and perspectives [J]. Pharm Res 16:176–185. https://doi.org/10.1080/15287390390227589
Ding CG (2006) Study on the Pharmacokinetics of scutellarin and an unknown metablite in animals. Shanghai Institute of pharmaceutical industry
Ding CG, Ge QH (2006) Pharmacokinetics of scutellarin in mice. Chin J Pharm Industry 37(1):26–31. https://doi.org/10.3969/j.issn.1001-8255.2006.01.012
Feng F, Shen YL (2006) Determination of trace scutellarin by a SPE-HPLC/MS/MS assay and its pharmcokinetics in human plasma. Chin J Pharm 41(6):457–460. https://doi.org/10.3321/j.issn:1001-2494.2006.06.018
Guo T, Li YY (2012) Progresses on pharmacological and toxicological effects of Dengzhanxixin injection. Chin J Trad Chin Med 37(18):2820–2823
He F (2005) Study on pharmacokinetics and intestinal flora metabolism of effective components of Erigeron breviscapus. Chengdu Univ Trad Chin Med. https://doi.org/10.7666/d.y766176
Hong L, Xian LY, Tang R et al (2005) Effects of Erigeron breviscapus ethanol extract on neuronal oxidative injury induced by superoxide radical. Fitoterapia 76(7/8):666–670. https://doi.org/10.1016/j.fitote.2005.08.014
Jia, M. R., Zhang, Y. (2016). Dictionary of Chinese ethnic medicine. Beijing: China Medical Science and Technology Press. 326
Jiang XH, Li SH, Lan K et al (2003) Study on the pharmacokinetics of scutellarin in dogs. Acta Pharm Sin 38(5):371
Ju WZ, Zhang J, Tan HS et al (2005) Determination of scutellarin in human plasma by LC-MS method and its clinical pharmacokinetics in Chinese healthy volunteers. Chin J Clin Pharmacol Therap 10(3):298–301. https://doi.org/10.3969/j.issn.1009-2501.2005.03.011
Li X (2018) Clinical effect of Dengzhanxixin injection on patients with ischemic stroke. Chin J Gerontol 38(16):15–16
Li J, Yu DQ (2011) Chemical constituents from herbs of Erigeron breviscapus. Chin J Trad Chin Med 36(11):1458–1462
Li R, Yan YL, Zhou LL et al (2002) Pharmacokinetics of Sini decoction. Chin Patent Med 24(10):777–780. https://doi.org/10.3969/j.issn.1001-1528.2002.10.014
Li WJ, Tao CG, Peng C (2007a) Pharmacokinetics of scutellarin in Breviscapine Injection in rats. Huaxi Pharmaceut J 22(5):520–522. https://doi.org/10.3969/j.issn.1006-0103.2007.05.015
Li WJ, Tao CG, Peng C (2007b) The pharmacokinetic study of caffeic acid esters after iv Erigeron Injection in rats. Pharmacol Clin Trad Chin Med 23(2):26–28. https://doi.org/10.3969/j.issn.1001-859X.2007.02.015
Li H, Zhang Y, Yu YP et al (2013) PK-PD study on antipyretic effect of rhubarb and its effect on reducing plasma nitric oxide. Chin J Trad Chin Med 38(8):1231–1236. https://doi.org/10.4268/cjcmm20130822
Liu YM, Lin AH, Chen H et al (2003) Study on pharmacokinetics of scutellarin in rabbits. Acta Pharm Sin 38(10):775
Ming LM, Yu NY, Ding LF et al (2007) Southern Yunnan materia medica. Yunnan Science and Technology Press, Kunming
Ruan ZP, Han D, Yuan M (2004) Determination of Scutellarin and its Pharmacokinetics Study in Rat by High Performance Liquid Chromatography with Electrochemical Detection. J Changzhi Med College 18(4):247–249. https://doi.org/10.3969/j.issn.1006-0588.2004.04.003
State Pharmacopoeia Commission (2015) Pharmacopoeia of the people's Republic of China (2015 edition, volume I). Beijing: China Pharmaceutical Science and Technology Press 147:873–874
Tian Y, Li Q, Zhou X et al (2017) A UHPLC-MS/MS method for simultaneous determination of twelve constituents from Erigeron breviscapus extract in rat plasma: application to a pharmacokinetic study. J Chromatogr B 1046:1–12. https://doi.org/10.1016/j.jchromb.2017.01.020
Wan, H. T., Guo, Y (2009). Pharmacokinetics of traditional Chinese medicine. Beijing: Chemical Industry Press. 183–218
Wang P, Miao SY, Meng XL (2009) Methodological study on Simultaneous Determination of five free anthraquinones from rhubarb in rat plasma by reversed phase ion pair chromatography. Pharmacol Clin Tradit Chin Med 25(5):47–49
Wang, Z., Meng, X. L., Zhang, Y., et al. (2015) A kind of fishline vascular thread bolt: China, zl201520311637.2
Wei, W., Wu, X. M., Li, Y. J. (2010). Pharmacology experimental methodology (4th Edition). Beijing:People's Health Press. 1003–1005
Wu SX, Chen XG, Li SM (2004) Therapeutic effect of breviscapine injection on hyperlipidemic cerebral infarction. J Clin Neurol 17(3):223–224. https://doi.org/10.3969/j.issn.1004-1648.2004.03.024
Xiao FX, Zhou LL, Li R et al (2001) Studies on pharmacokinetic parameters of Aconitine in Sini decoction by determining blood-drug concentrations. J Guangzhou Univ Trad Chin Med 18(3):243–246. https://doi.org/10.3969/j.issn.1007-3213.2001.03.015
Xiao FX, Zhou LL, Li R (2005) Pharmacokinetics of Aconitum alkaloids in Sini Decoction. J Chin Med Materials 28(7):587–588. https://doi.org/10.3321/j.issn:1001-4454.2005.07.024
Xu JM, Huang ZH (1991) Erigeron breviscapus capsule in the treatment of cerebrovascular disorders in 74 patients. New Drugs Clin 10(5):260–263
Yan DM, Kang LY, Hu LM (2009) Overview of pharmacokinetics of Erigeron breviscapus. World Sci Technol - Modernization Trad ChinMed 11(2):299–303. https://doi.org/10.11842/wst.2009.2.[sequence]
Yang, B. F. (2013) Pharmacology (8th Edition). Beijing: People's Health Press. 22
Yang FH, Zhong YA, Yang FH et al (2014) Clinical observation of Dengzhan Xixin injection in treating cerebral infarction. Chin New Clin Med 7(9):843–845. https://doi.org/10.3969/j.issn.1674-3806.2014.09.14
Yin WW, Chen S, Bi K et al (2017) Study on effect of lamps Asarum injection on acute cerebral infarction patients with serum HIF-1α, caspase-3 and blood uric acid levels. Liaoning J Trad Chin Med 044(005):996–998
Yu YP, Zhang Y, Li H et al (2014) PK-PD model of antipyretic effect of Baicalin on carrageenan induced rats. Chin Herbal Med 45(4):527–531. https://doi.org/10.7501/j.issn.0253-2670.2014.4.014
Zeng J, Wang SJ, Yang BK et al (2012) The research progresses of the PK-PD modeling. J Guangdong Pharm College 28(4):461–465. https://doi.org/10.3969/j.issn.1006-8783.2012.04.027
Zhang J (2008) Study on the substance basis of brain targeted neuroprotective effect of Erigeron breviscapus. Doctoral Dissertation Chengdu Univ Trad Chin Med. https://doi.org/10.7666/d.d166248
Zhang ZP, Yang ZX, Li PH et al (2014) Study of scutellarin and scutellarin biosynthesis in Glycosidation reaction reac. Trad Med Asia Pacific 10(10):16–22
Zhang, X., Zheng, W., Wang T., et al (2016) Danshen-Chuanxiong-Honghua ameliorates cerebral impairment and improves spatial cognitive deficits after transient focal ischemia and identification of active compounds. Front Pharmacol 8
Zhong XJ, Cheng J (2018) Effect of Dengzhanxixin injection on short-term oxidation, hemorheology and neurological deficits in treatment of cerebral infarction. J Clin Exp Med 2(17):144–147. https://doi.org/10.3969/j.issn.1671-4695.2018.02.011
Acknowledgments
This work was supported by the National Natural Science Foundation of China (no. 81102895), the Special Scientific Research Fund for Doctoral Programs of Higher Education in China’s Ministry of Education (no. 20115132120007), the Key Project of Sichuan Province Applied and Basic Research Program (no. 2016JY0017) and the First Batch of Young Chinese Medicine Research Special Program of Sichuan Provincial Chinese Medicine Administration (no. 2016Q051).
Author information
Authors and Affiliations
Contributions
GL conducted the chemical composition analysis of Erigeron breviscapus injection and the main writing of the article; GT participated in the literature search and pharmacodynamic research; WL and WX conducted the pharmacodynamics and pharmacokinetic studies; ZW was the author of the communication; GF and YW participated in the guided experimental study; and MZ participated in the pharmacodynamic study.
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that there are no conflicts of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Liu, G., Tang, G., Liang, W. et al. PK-PD Correlation of Erigeron Breviscapus Injection in the Treatment of Cerebral Ischemia-Reperfusion Injury Model Rats. J Mol Neurosci 71, 302–324 (2021). https://doi.org/10.1007/s12031-020-01651-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-020-01651-3